In a hydridoma fusion aimed at preparing monoclonal antibody against the tumour-associated Thomsen-Friedenreich (T) antigen we have obtained a product, designated B5, with the unexpected property of agglutinating erythrocytes from patients with malignant disease.
Summary In haemagglutination tests we have found that the monoclonal antibody B5 discriminates between erythrocytes from patients with malignant cancer (total 386; >80% B5 positive) and individuals with no known tumour (total 247; <20% B5 positive). The B5 antigen detected on intact erythrocytes is a tightly bound surface component which does not appear to be derived from the plasma. The B5 antigen is not T, Tn, Cal, CEA or the Forsmann antigen; nor is it related to any of the major blood group antigens. Abnormal levels of surface B5 are found on erythrocytes from patients with a great diversity of tumours and this fact presents B5 as an indirect marker of malignancy. Successful eradication of tumour is associated with a switch from positive to negative B5 haemagglutination. We believe that B5 is a valuable addition to the few useful tumour markers already employed for monitoring tumour status.
In a hydridoma fusion aimed at preparing monoclonal antibody against the tumour-associated Thomsen-Friedenreich (T) antigen we have obtained a product, designated B5, with the unexpected property of agglutinating erythrocytes from patients with malignant disease.
The Thomsen-Friedenreich (T) antigen is a component of the human erythrocyte membrane which is normally occluded by sialic acid (Friedenreich, 1930) . Initially B5 appeared to be anti-T since it agglutinated desialylated, but not intact erythrocytes and was neutralised by purified glycophorin (T-antigenic glycoprotein kindly donated by G.F. Springer). It was only a later, definitive analysis which showed that B5 was not anti-T since it did not react with the T-determinant (Springer et al., 1975 and Springer, personal communication) . In the meantime, attempts to stain leukaemic cells for T-antigen using B5 had, not surprisingly, failed. However, when B5 was added to the erythrocytes from these leukaemic patients there was strong haemagglutination: this result was unexpected since we knew that B5 did not agglutinate erythrocytes from a normal donor. Preliminary testing revealed that cancer patients in general are positive for B5 haemagglutination (Milner & Metcalfe, 1982) fusion between Y3-Agl.2.3. rat myeloma cells (Galfre et al., 1979) and spleen cells from an AO rat immunised with desialylated human erythrocytes (blood group 0). Each immunising dose was of 109 cells, the priming dose being in complete Freund's adjuvant and intramuscular (i.m.). The first i.m. boost was in incomplete Freund's and the second i.m. boost was without adjuvant, each being at 4 week intervals. Three days after a final i.v. boost, spleen cells were collected and fused with the Y3 cells using polyethylene glycol (B.D.H., mol. wt 1500) by standard procedure. Those supernatants which caused agglutination of desialylated, but not whole, erythrocytes were regarded as positive. In the fusion from which B5 was obtained, B5 was the only positive clone: in subsequent fusions a large number of positive supernatants have been found, though none have the binding properties of B5 (see results). In this study we have used a pool of supernatant with a titre of 1/128 against desialylated erythrocytes. An equivalent titre was maintained after storage of cloned cells in liquid nitrogen.
Haemagglutination tests require a small volume of heparinised blood: in this study 5ml was taken, although 1ml would be ample. Appropriate conditions for storage were assessed by testing aliquots from samples kept at 4°C. Storage for up to 7 days in these conditions did not alter the B5-haemagglutination properties compared to the fresh sample. For assay, 1 ml of whole blood was washed 3 times in 20 ml PBS, pH 7.4, at room temperature. A small volume of washed, packed erythrocytes was then diluted to 1% in PBS containing 4% foetal calf serum (FCS) and 25 pl of this suspension was added to 25 ,ul B5 antibody in a "U" well haemagglutination plate. In controls 1% erythrocytes were added to PBS containing 4% FCS. or to culture supernatant containing an irrelevant antibody. The plates were covered with film and left for at least 2 h at room temperature before being read. Haemagglutination was scored positive or negative using an inverted microscope to view the pellets directly under low power. Each sample was also scored by direct examination of cells gently resuspended and transferred onto a glass slide. In the latter method clusters of less than ten cells and representing <20% of the total were regarded as negative; the rest scored positive.
Trypsin treatment was with 0.125% trypsin in Ca + + Mg + + -free PBS at room temperature. Neuraminidase was used at 1 i.u. ml-1 in 0.85% NaCl containing 10-3M CaCl2 and incubated at 37°C for 2 h unless otherwise stated: this treatment causes extensive desialylation of the membrane surface.
Results

Clinical
In the clinical survey we found that the B5 haemagglutination test discriminates between erythrocytes from patients with malignant disease and erythrocytes from individuals with no known malignancy. The results given in Tables I and II show that >80% of patients (total 386) with various types of cancer were B5 positive. These include each of 6 patients with tumours affecting the central nervous system, a tumour type rarely detected by other markers. Since the incidence of B5 positivity was 80% in tumour patients and -20% in each of the control groups, we conclude that erythrocyte surface B5 antigen is markedly increased in individuals who develop malignant tumour. So far we have insufficient data to know if B5 also discriminates between malignant and benign tumours, though preliminary results comparing women with benign and malignant breast disease showed a lower incidence of B5 positively in pre-operative samples from the benign group (4/8) in contrast to those with malignant disease (12/13).
It is important to know whether successful treatment of malignancy is associated with a switch from B5 positive to B5 negative. For this purpose data is now being accumulated in serial studies on individual patients, and preliminary results indicate that B5 haemagglutination decreases with time during treatment when no active disease is detectable (Table III) . In addition, 14/15 patients who had completed treatment for malignancy were B5 negative (Table III) difference in the source of B5 antigen detected in these two groups, and thus it was of interest to determine whether the antigen is acquired, or exposed through abnormal desialylation of the cell surface. We have attempted to discriminate between these two possibilities in experiments summarised in Table IV . First, we found that brief trypsinisation of intact B5-positive cells from normal or tumour patients completely abolished B5-haemagglutination: as expected B5-negative cells remained negative following trypsin treatment. The trypsinised form of each cell preparation became strongly B5-positive when desialylated, thus showing that both B5 positive and B5 negative cells have an occluded population of B5 antigen. A second treatment with trypsin of these now desialylated cells caused a reduction in B5 haemagglutination which was similar for each preparation. These observations suggest that surface B5 antigen on erythrocytes from both normal and tumour patients is in addition to, rather than a part of, the occluded antigen. Although sensitive to trypsin, surface B5 seemed to be tightly associated with the membrane in that it could not be removed by 1 mM EDTA. Whilst we have not yet identified the nature of the surface B5 antigen, haemagglutination tests with the relevant monoclonal antibodies and lectins have excluded the following known antigens as candidates: T, Tn, carcinoembryonic antigen (CEA), Cal and the Forsmann antigen. Comparison of donor blood group with B5-haemagglutination showed no correlation of surface B5 antigen with any of the major blood group antigens.
We next considered the possibility that surface B5 antigen may be acquired from the plasma, first by screening plasma for free B5 antigen, and 87 (98) 84 (85) 26 (166) 10 (20) 3 (5) 1 (1) 1 (1) 1 (1) 1 (5) 1 (1) 29 (37) 21 (31) 16 (20) 17 (21) 10 (10) 7 (7) 6 (10) (3) 3 (3) 3 (3) 3 (3) 2 (2) 1 (1) 1 (1) 1 (1) 1 (1)
9 (12) 1 (1) 386 (598 chemotherapy and/or radiotherapy. In serial studies our finding that some tumour patients who had been consistently B5 positive became B5 negative towards the end of therapy, encourages us to believe that such a switch from positive to negative may indicate successful treatment of tumour. Since the only requirement is a small blood sample, B5 provides a very simple, non-invasive test applicable to a wide range of malignancies. We feel its greatest worth will be in the monitoring of individuals for tumour status, both for tumour regression during therapy, and for tumour recurrence during followup.
